Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities?
- 15 October 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 102 (8) , 3073-3074
- https://doi.org/10.1182/blood-2003-07-2274
Abstract
Clinical presentation in adults with SMCD is markedly heterogeneous,2 and making or refuting the diagnosis requires a careful morphologic analysis of the bone marrow. In general, SMCD is characterized by focal, dense aggregates of dysplastic MCs. However, the bone marrow MC infiltration pattern in aggressive SMCD, including SMCD-eos, can be diffuse, and whether one appreciates a “dense” or “loose” scattering of MCs in this setting is open to subjective bias.3 In our experience, either dense or loose aggregates of dysplastic MCs are seen in both FIP1L1-PDGFRA+ and c-kit D816V+ SMCD-eos. This was illustrated in a recent report of 5 patients with SMCD-eos in which all 3 patients who carried the FIP1L1-PDGFRA fusion had pathognomonic MC aggregates in the bone marrow in a pattern that was not different from 1 of the patients with the c-kit D816V mutation.4Keywords
This publication has 11 references indexed in Scilit:
- CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapyBlood, 2003
- Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsivenessBlood, 2003
- Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophiliaLeukemia Research, 2003
- Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disordersBlood, 2003
- A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic SyndromeNew England Journal of Medicine, 2003
- Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell diseaseLeukemia Research, 2003
- Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorderBritish Journal of Haematology, 2003
- PDGFRA Activating Mutations in Gastrointestinal Stromal TumorsScience, 2003
- Systemic Mast Cell Disease Without Associated Hematologic Disorder: A Combined Retrospective and Prospective StudyMayo Clinic Proceedings, 2002
- Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemiaThe EMBO Journal, 2000